| Chapter title |
Money and Morals : Ending Clinical Trials for Financial Reasons.
|
|---|---|
| Chapter number | 337 |
| Book title |
Ethical Issues in Behavioral Neuroscience
|
| Published in |
Current topics in behavioral neurosciences, July 2014
|
| DOI | 10.1007/7854_2014_337 |
| Pubmed ID | |
| Book ISBNs |
978-3-66-244865-6, 978-3-66-244866-3
|
| Authors |
Margaret L Eaton, Brian K Kwon, Christopher Thomas Scott, Margaret L. Eaton, Brian K. Kwon, Eaton, Margaret L., Kwon, Brian K., Scott, Christopher Thomas |
| Editors |
Grace Lee, Judy Illes, Frauke Ohl |
| Abstract |
Too often, biopharmaceutical companies stop their clinical trialsClinical trials solely for financial reasons. In this chapter, we discuss this phenomenon against the backdrop of a 2011 decision by Geron Corporation to abandon its stem cell clinical trial for spinal cord injury (SCI), the preliminary results of which were released in May 2014. We argue that the resultant harms are widespread and are different in nature from the consequences of stopping trials for scientific or medical reasons. We examine the ethical and social effects that arise from such decisions and discuss them in light of ethical frameworks, including duties of individual stakeholders and corporate sponsors. We offer ways that sponsors and clinical sites can ensure that trials are responsibly started, and once started adequately protect the interests of participants. We conclude with recommendations that industry sponsors of clinical trialsClinical trials should adopt in order to advance a collective and patient-centered research ethic. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 15% |
| United States | 1 | 8% |
| Sweden | 1 | 8% |
| Spain | 1 | 8% |
| Canada | 1 | 8% |
| Unknown | 7 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 54% |
| Scientists | 5 | 38% |
| Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Canada | 1 | 3% |
| Unknown | 31 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 21% |
| Student > Ph. D. Student | 3 | 9% |
| Student > Bachelor | 3 | 9% |
| Other | 2 | 6% |
| Lecturer | 1 | 3% |
| Other | 5 | 15% |
| Unknown | 12 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 27% |
| Arts and Humanities | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Business, Management and Accounting | 1 | 3% |
| Other | 5 | 15% |
| Unknown | 15 | 45% |